NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.


Don't have an account? Subscribe

Irish Blood Transfusion Service plan to develop ‘allogeneic tears’

By Mindo - 19th Sep 2018

The Service has drawn-up a business plan that will be presented internally, an IBTS spokesperson informed <strong><em>MI</em></strong>. “The rationale is that there is a demand for this product from patients and we have the opportunity to develop it,” they outlined. 

Galway University Hospital is licensed to produce serum eye drops (SED), a serum-derived product used to treat a range of ocular surface disorders. According to the HSE website, the hospital obtained a Good Manufacturing Practice (GMP) license to produce autologous and allogeneic serum eye drops.

The IBTS’s spokesperson said the Service’s internal business case will be considered by the Executive Management Team and the Board.

“At present, the IBTS supplies the serum to Galway University Hospital and they make the eye drops. The IBTS is looking at doing the complete process,” explained the spokesperson.

According to clinical guidelines from the Royal College of Ophthalmologists, UK, SED are a useful adjunctive treatment for patients with severe ocular surface disease, especially those with a compromised tear film.

“Serum contains a large number of epitheliotropic factors that are present in tears. These factors are likely to be responsible for the therapeutic benefits observed with SED therapy compared to conventional commercially-available ocular lubricants,” according to the guidelines.

“Prescribed and over-the-counter tear substitutes primarily alleviate symptoms through reduction of friction and shear-forces caused by blink-induced biomechanical trauma. This mechanism of action appears largely to be independent of structural chemistry and viscosity of the lubricant product. By contrast, SED provide a variety of nutritional molecules, such as vitamins, glucose, growth factors and immunoglobulins. These help to restore an environment that promotes re-epithelialisation and supports ocular surface health.”

Leave a Reply

Latest
Latest Issue
The Medical Independent 20th February
The Medical Independent 20th February 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read